Disease relapse is a major barrier to long-term remission in AML and is attributed to the presence of measurable residual disease (MRD). MRD assessment is established for prognostication and therapeutic guidance in AML, but only a handful of MRD markers are currently recognized for this purpose. We aim to validate the prognostic impact of novel MRD markers and assays and gain further insight into what drives resistance in these MRD cells using single cell technologies. Additionally, we have established a world first multi-domain, adaptive platform trial, ALLG AMLM26: INTERCEPT, which aims to facilitate the proof-of-concept development of new therapies and combinations for patients with increasing MRD in AML according to the MRD biomarker present.
Name: Natasha Anstee (post-doctoral fellow)
In collaboration with: Sun Loo, Yin Yuan, Jafar Jabbari